The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts.

[1]  J. Oliveira,et al.  The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts , 2019, Molecular genetics and metabolism reports.

[2]  J. Oliveira,et al.  European expert consensus statement on therapeutic goals in Fabry disease. , 2018, Molecular genetics and metabolism.

[3]  Y. Iso,et al.  Therapeutic impact of cardiac rehabilitation exercise on cardiac Fabry woman treated with enzyme replacement therapy , 2016 .

[4]  J. Stypmann,et al.  Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  W. Shimizu,et al.  Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease. , 2016, International heart journal.

[6]  J. Charrow,et al.  Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. , 2016, Molecular genetics and metabolism.

[7]  R. Bazan,et al.  Enzyme replacement therapy for Anderson-Fabry disease. , 2016, The Cochrane database of systematic reviews.

[8]  H. Yoo,et al.  Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes , 2016, Journal of Human Genetics.

[9]  D. Shah,et al.  The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy , 2016, Heart.

[10]  Manesh R. Patel,et al.  Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry , 2016, Journal of Medical Genetics.

[11]  C. Hollak,et al.  Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort. , 2016, Molecular genetics and metabolism.

[12]  J. Politei,et al.  Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations – different outcome? , 2016, Clinical genetics.

[13]  A. Hagège,et al.  X‐chromosome inactivation in female patients with Fabry disease , 2016, Clinical genetics.

[14]  I. Law,et al.  Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up , 2015, PloS one.

[15]  M. Beck,et al.  Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment , 2015, Orphanet Journal of Rare Diseases.

[16]  Z. Bicik,et al.  Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease. , 2015, Iranian journal of kidney diseases.

[17]  J. Kuusisto,et al.  Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease , 2015, Drug design, development and therapy.

[18]  K. Ohno,et al.  A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes. , 2015, Clinical Nephrology.

[19]  W. Dreschler,et al.  Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy , 2015, Journal of Inherited Metabolic Disease.

[20]  A. Mehta,et al.  Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis , 2015, Molecular genetics and metabolism reports.

[21]  Wen-Chung Yu,et al.  Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A) , 2014, Orphanet Journal of Rare Diseases.

[22]  W. Henley,et al.  Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study , 2014, Journal of Inherited Metabolic Disease.

[23]  S. Doucette,et al.  Outcomes of patients treated through the Canadian Fabry disease initiative. , 2014, Molecular genetics and metabolism.

[24]  Hiroshi Yamamoto,et al.  Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α , 2014, Genetics in Medicine.

[25]  B. Bibby,et al.  Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  Anatália Labilloy,et al.  Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease. , 2014, Gene.

[27]  M. Dijkgraaf,et al.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis , 2014, Journal of Inherited Metabolic Disease.

[28]  H. Kojima,et al.  Long-Term Effect of Enzyme Replacement Therapy with Fabry Disease , 2013, International journal of otolaryngology.

[29]  Hsiang-Yu Lin,et al.  Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) , 2013, BMJ Open.

[30]  Manesh R. Patel,et al.  Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry , 2013, Genetics in Medicine.

[31]  M. Dijkgraaf,et al.  Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain , 2013, Orphanet Journal of Rare Diseases.

[32]  C. Auray-Blais,et al.  Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. , 2013, Analytical chemistry.

[33]  C. Hollak,et al.  Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome , 2012, PloS one.

[34]  K. Hirata,et al.  Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease , 2012, Clinical kidney journal.

[35]  C. Hollak,et al.  Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine , 2012, Hypertension.

[36]  R. Desnick,et al.  Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. , 2012, Annual review of genomics and human genetics.

[37]  M. Motwani,et al.  Enzyme replacement therapy improves cardiac features and severity of Fabry disease. , 2012, Molecular genetics and metabolism.

[38]  Hiroshi Yamamoto,et al.  Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal) , 2012, Genetics in Medicine.

[39]  J. Politei,et al.  Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. , 2012, Human pathology.

[40]  C. Sommer,et al.  Small fibers in Fabry disease: baseline and follow‐up data under enzyme replacement therapy , 2011, Journal of the peripheral nervous system : JPNS.

[41]  C. Hollak,et al.  Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients , 2011, Orphanet journal of rare diseases.

[42]  J. Oliveira,et al.  Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  C. Hollak,et al.  Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey. , 2011, Molecular genetics and metabolism.

[44]  J. Oliveira,et al.  Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[45]  D. Germain.  Fabry disease , 2010, Orphanet journal of rare diseases.

[46]  R. Hopkin,et al.  Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry , 2010, Genetics in Medicine.

[47]  C. Hollak,et al.  Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests , 2010, BMC neurology.

[48]  J. Politei.  Treatment with agalsidase beta during pregnancy in Fabry disease , 2010, The journal of obstetrics and gynaecology research.

[49]  C. Hollak,et al.  Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy. , 2010, Placenta.

[50]  P. Bruneval,et al.  Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report. , 2010, European journal of medical genetics.

[51]  Manesh R. Patel,et al.  Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry , 2009, Genetics in Medicine.

[52]  G. Gambaro,et al.  Unusual renal presentation of Fabry disease in a female patient , 2009, Nature Reviews Nephrology.

[53]  A. Gal,et al.  A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease , 2009, Genetics in Medicine.

[54]  K. Murao,et al.  Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease. , 2009, The Tohoku journal of experimental medicine.

[55]  S. Feriozzi,et al.  Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease , 2008, American Journal of Nephrology.

[56]  W. Wilcox,et al.  Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage , 2008, Journal of Inherited Metabolic Disease.

[57]  G. Siciliano,et al.  Central nervous system involvement in Anderson–Fabry disease: a clinical and MRI retrospective study , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[58]  J. Oliveira,et al.  Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. , 2008, Molecular genetics and metabolism.

[59]  P. Arnaud,et al.  Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women , 2008, European Journal of Clinical Pharmacology.

[60]  A. Mehta,et al.  Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[61]  D. Straumann,et al.  Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy , 2007, Journal of Neurology.

[62]  K. Tsuboi.  Enzyme Replacement Therapy in Patients with Fabry's Disease , 2007, The Journal of international medical research.

[63]  Atul Mehta,et al.  Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey , 2007, The Clinical journal of pain.

[64]  A. Santoro,et al.  Endocrine dysfunction in patients with Fabry disease. , 2006, The Journal of clinical endocrinology and metabolism.

[65]  S. Brodie,et al.  Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement , 2006, Genetics in Medicine.

[66]  M. Elleder,et al.  Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population , 2005, Journal of Molecular Medicine.

[67]  G. Maguire,et al.  Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide , 2005, Journal of Inherited Metabolic Disease.

[68]  R. Desnick.  Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approval , 2004, Expert opinion on biological therapy.

[69]  D. Straumann,et al.  Head‐impulse testing in Fabry disease ‐ vestibular function in male and female patients , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[70]  F. Baehner,et al.  Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study , 2003, Journal of Inherited Metabolic Disease.

[71]  S. Waldek.  PR interval and the response to enzyme-replacement therapy for Fabry's disease. , 2003, The New England journal of medicine.

[72]  G. Abor,et al.  Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease , 2001 .

[73]  C. Eng,et al.  Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). , 1999, American journal of medical genetics.

[74]  A. Kahn,et al.  Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the α-galactosidase A gene and detection of carriers in Fabry disease , 1996, Human Genetics.

[75]  C. Wanner,et al.  The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. , 2019, Molecular genetics and metabolism.

[76]  F. Weidemann,et al.  Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. , 2018, JIMD reports.

[77]  G. Oǧur,et al.  Management of neuropathic pain in fabry disease , 2016 .

[78]  Hiroshi Yamamoto,et al.  Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)). , 2015, JIMD reports.

[79]  P. Chang,et al.  Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa. , 2015, JIMD reports.

[80]  A. Tuttolomondo,et al.  A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene. , 2015, Clinical biochemistry.

[81]  D. Sillence,et al.  Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience. , 2012, JIMD reports.

[82]  S. Feriozzi,et al.  The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[83]  A. Zwinderman,et al.  Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. , 2011, Biochimica et biophysica acta.

[84]  B. Bénichou,et al.  A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. , 2009, Molecular genetics and metabolism.

[85]  D. Horstkotte,et al.  Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry’s disease during enzyme-replacement therapy , 2009, Clinical Research in Cardiology.

[86]  D. Germain.  A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. , 2001, Contributions to nephrology.

[87]  G. Abor,et al.  Uva-dare (digital Academic Repository) Safety and Efficacy of Recombinant Human Alpha-galactosidase a Replacement Therapy in Fabry's Disease Safety and Efficacy of Recombinant Human a -galactosidase a Replacement Therapy in Fabry's Disease , 2022 .